Funds › Acorn Capital Advisors, LLC
Acorn Capital Advisors, LLC
13F for Q2 2026, filed Aug 14, 2026. 20 positions worth $366.5M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Acorn Capital Advisors, LLC in the latest 13F quarter?
Using 13F.ai, how has Acorn Capital Advisors, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Acorn Capital Advisors, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q2 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | CGON CG Oncology, Inc. | 1.13M | $80.4M | 21.9% | +0.1% | 13F ↗ |
| 2 | URGN UroGen Pharma Ltd. | 1.67M | $61.6M | 16.8% | Unchanged | 13F ↗ |
| 3 | TRVI Trevi Therapeutics, Inc. | 2.14M | $40.0M | 10.9% | Unchanged | 13F ↗ |
| 4 | CADL Candel Therapeutics, Inc. | 3.50M | $36.0M | 9.8% | Unchanged | 13F ↗ |
| 5 | PBYI Puma Biotechnology Inc | 4.13M | $33.5M | 9.1% | Unchanged | 13F ↗ |
| 6 | JBIO Jade Biosciences, Inc. | 986,760 | $21.9M | 6.0% | +25.4% | 13F ↗ |
| 7 | BCAX Bicara Therapeutics Inc. | 643,381 | $19.1M | 5.2% | Unchanged | 13F ↗ |
| 8 | KPTI Karyopharm Therapeutics Inc. | 1.52M | $14.8M | 4.0% | +427% | 13F ↗ |
| 9 | OKUR OnKure Therapeutics, Inc. | 2.84M | $12.9M | 3.5% | Unchanged | 13F ↗ |
| 10 | Cybin Inc | 1.54M | $10.2M | 2.8% | Unchanged | 13F ↗ |
| 11 | TARA Protara Therapeutics, Inc. | 1.75M | $6.7M | 1.8% | Unchanged | 13F ↗ |
| 12 | AURA Aura Biosciences, Inc. | 929,077 | $6.6M | 1.8% | +56.0% | 13F ↗ |
| 13 | LONA LeonaBio, Inc. | 634,539 | $5.8M | 1.6% | Unchanged | 13F ↗ |
| 14 | VSTM Verastem, Inc. | 1.47M | $5.6M | 1.5% | Unchanged | 13F ↗ |
| 15 | WHWK Whitehawk Therapeutics, Inc. | 1.14M | $5.2M | 1.4% | Unchanged | 13F ↗ |
| 16 | QTTB Q32 Bio Inc. | 216,171 | $2.8M | 0.8% | -31.4% | 13F ↗ |
| 17 | ENGN enGene Therapeutics Inc. | 1.27M | $2.2M | 0.6% | New | 13F ↗ |
| 18 | JSPR Jasper Therapeutics, Inc. | 1.44M | $604.0K | 0.2% | +1.9% | 13F ↗ |
| 19 | Bioatla Inc | 108,126 | $447.6K | 0.1% | -98.0% | 13F ↗ |
| 20 | Vyne Therapeutics Inc | 1,425 | $926 | <0.1% | Unchanged | 13F ↗ |
Changes since Q1 2026
1 new, 5 added to, 3 trimmed, 3 exited, 11 unchanged. By estimated dollars.
New positions (1)
| Position | Shares | Change | Est. dollars |
|---|---|---|---|
| ENGN enGene Therapeutics Inc. | 1.27M | New | $2.2M |
Added to (5)
Trimmed (3)
Exited (3)
| Terns Pharmaceuticals Inc | 1.75M | Exited | -$92.1M |
| CRDF Cardiff Oncology, Inc. | 1.76M | Exited | -$2.9M |
| X4 Pharmaceuticals, Inc | 234,039 | Exited | -$966.6K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q2 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 13F-HR | 20 | $366.5M | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR | 22 | $351.8M | Current | SEC ↗ |
| Q4 2025 | Feb 17, 2026 | 13F-HR | 21 | $295.1M | Current | SEC ↗ |
| Q3 2025 | Nov 17, 2025 | 13F-HR | 20 | $197.0M | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 21 | $152.9M | Current | SEC ↗ |
| Q1 2025 | May 19, 2025 | 13F-HR/A (restatement) | 22 | $149.9M | Current | SEC ↗ |
| Q1 2025 | May 15, 2025 | 13F-HR | 22 | $143.7M | Replaced | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer